Ownership Summary
According to SEC filings for the period ending December 2025, Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) is held by 8 institutional firms.
- Shuttle Pharmaceuticals Holdings saw its institutional ownership percentage fell to 3.5% in December 2025 from 10.6% in September 2025.
- Quarterly data indicates a 4391.04% shift in institutional share volume, and the annual owner count reflects an increase of 14.29%.
- The latest 13F cycle for Shuttle Pharmaceuticals Holdings reveals that of 8 total investors, 5 funds grew their exposure, whereas 1 reduced theirs and 2 made no changes.
- The total number of shares held by institutions in Shuttle Pharmaceuticals Holdings increased to 47.60K as of December 2025, a net change of up by 46.55K shares quarter on quarter, and down 309.06K shares year over year.
- BOOTHBAY FUND MANAGEMENT, LLC's holding of 20.36K shares as of December 31, 2025 makes it the primary institutional investor in Shuttle Pharmaceuticals Holdings, owning 1.49% of the stock.
- Among the most significant buyers of Shuttle Pharmaceuticals Holdings during December 2025 were BOOTHBAY FUND MANAGEMENT, LLC (20.36K), GEODE CAPITAL MANAGEMENT, LLC (14.44K), UBS Group AG (11.94K), BANK OF AMERICA CORP /DE/ (4), CITIGROUP INC (1).
- Leading sellers of Shuttle Pharmaceuticals Holdings stock in December 2025 included Tower Research Capital LLC (TRC) (203).
- The top 8 institutional holders of Shuttle Pharmaceuticals Holdings for the quarter ending December 2025 included BOOTHBAY FUND MANAGEMENT, LLC (20.36K), GEODE CAPITAL MANAGEMENT, LLC (14.44K), UBS Group AG (11.95K), Tower Research Capital LLC (TRC) (812), MORGAN STANLEY (27), BANK OF AMERICA CORP /DE/ (12), Federation des caisses Desjardins du Quebec (2), CITIGROUP INC (1).